Immunome Inc. (IMNM)

Name: Immunome Inc. (IMNM) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001472012 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Immunome Inc. reported revenue of $6.94M. Revenue fell 23.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $0.

Key ratios (year ended 2025-12-31)

n/m

Operating margin

n/m

Net margin

-33.5%

Return on year-end equity

-23.2%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31
Revenue	$0	$6.94M	$9.04M	$14.02M	n/a	n/a	n/a	n/a
R&D Expense	$206.23M	$177.29M	$129.54M	$23.09M	$23.27M	$14.11M	$7.49M	$8.82M
Operating Income	-$270.46M	-$224.11M	-$305.80M	-$109.53M	-$36.90M	-$25.20M	-$12.26M	-$10.35M
Depreciation & Amortization	$2.78M	$2.47M	$1.57M	$457.0K	$422.0K	$755.0K	$755.0K	$615.0K
EBITDA	-$267.69M	-$221.65M	-$304.23M	-$109.07M	-$36.48M	-$24.45M	-$11.51M	-$9.73M
Net Income	-$254.32M	-$212.39M	-$292.96M	-$106.81M	-$36.90M	-$24.71M	-$17.84M	-$10.44M
EPS (Diluted)	n/a	-$2.43	-$5.00	-$5.38	-$3.09	-$2.14	-$5.26	n/a
Total Assets	$565.38M	$683.19M	$240.24M	$148.54M	$24.05M	$57.92M	$44.52M	$5.06M
Total Liabilities	$40.30M	$48.84M	$59.08M	$28.66M	$7.39M	$9.74M	$3.18M	$1.80M
Long-Term Debt	n/a	n/a	n/a	n/a	n/a	n/a	$500.0K	n/a
Shareholders' Equity	$525.08M	$634.34M	$181.16M	$119.88M	$16.65M	$48.19M	$41.34M	-$35.63M
Cash & Equivalents	$217.71M	$653.48M	$143.35M	$98.68M	$20.32M	$49.23M	$39.77M	$2.54M
Operating Cash Flow	-$208.79M	-$190.92M	-$110.79M	-$7.57M	-$28.69M	-$18.23M	-$12.13M	-$9.60M
Capital Expenditures	$10.29M	$9.69M	$7.17M	$831.0K	$248.0K	$79.0K	$586.0K	$233.0K
Free Cash Flow	-$219.09M	-$200.60M	-$117.97M	-$8.40M	-$28.94M	-$18.30M	-$12.72M	-$9.83M
Shares Outstanding	113.40M	113.13M	64.46M	43.25M	12.13M	12.11M	10.63M	1.10M
Weighted Average Diluted Shares	n/a	87.35M	58.64M	19.84M	12.13M	11.54M	3.39M	n/a
EPS (Basic)	n/a	-$2.43	-$5.00	-$5.38	-$3.09	-$2.14	-$5.26	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView